Doxorubicin: Role in the treatment of osteosarcoma
作者： Susan M. Blaney , Malcolm A. Smith , Jean L. Grem
DOI: 10.1007/978-1-4615-3518-8_10
关键词:
摘要: The objective of this chapter is to review the role that doxorubicin (DOX), one most active single agents for treatment osteosarcoma, has played in neoadjuvant and adjuvant osteosarcoma during past several decades. A brief mechanism action, pharmacokinetics, pharmacodynamics DOX will be presented, since an understanding these parameters essential optimal use agent. Results from recent clinical trials have incorporated (either alone or combination chemotherapy regimens) then reviewed, potential strategies maximize antitumor future regimens discussed. comprehensive published 1988 by Grem et al. [1] updated, reference citation limited literature (1988 present).
springer.com
elsevier.com
sci-hub.st 参考文章(37)
B. A. Chabner, D. L. Longo, H. M. Pinedo, Cancer chemotherapy and biological response modifiers annual Elsevier. ,(1987)
G. L. Scheffer, H. Joenje, D. Housman, F. Baas, M. Van Groenigen, A. Riethorst, H. J. Broxterman, A. P M Jongsma, R. J. Arceci, A. W M Nieuwint, Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Research. ,vol. 50, pp. 5392- 5398 ,(1990)
Leonard Sender, Mitchell S. Cairo, Nick Anas, Stuart Siegel, Clinical Trial of Continuous Infusion Verapamil, Bolus Vinblastine, and Continuous Infusion VP-16 in Drug-resistant Pediatric Tumors Cancer Research. ,vol. 49, pp. 1063- 1066 ,(1989)
Birandra K. Sinha, Charles E. Myers, Pedro M. Politi, Sankaran Rajagopalan, Adriamycin-induced Free Radical Formation in the Perfused Rat Heart: Implications for Cardiotoxicity Cancer Research. ,vol. 48, pp. 4766- 4769 ,(1988)
H. Joenje, J. Lankelma, J. van Rijn, G.J. Schuurhuis, H.G. Keizer, W.G.E.J. Schoonen, H.J. Broxterman, H.M. Pinedo, Correlation of multidrug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells Cancer Research. ,vol. 49, pp. 2988- 2993 ,(1989)
W S Dalton, T M Grogan, P S Meltzer, R J Scheper, B G Durie, C W Taylor, T P Miller, S E Salmon, Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Journal of Clinical Oncology. ,vol. 7, pp. 415- 424 ,(1989) , 10.1200/JCO.1989.7.4.415
T P Miller, T M Grogan, W S Dalton, C M Spier, R J Scheper, S E Salmon, P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology. ,vol. 9, pp. 17- 24 ,(1991) , 10.1200/JCO.1991.9.1.17
A Rahman, J Treat, J K Roh, L A Potkul, W G Alvord, D Forst, P V Woolley, A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. Journal of Clinical Oncology. ,vol. 8, pp. 1093- 1100 ,(1990) , 10.1200/JCO.1990.8.6.1093
David G. Poplack, Philip A. Pizzo, Principles and Practice of Pediatric Oncology ,(1989)
K Winkler, G Beron, G Delling, U Heise, H Kabisch, C Purfürst, J Berger, J Ritter, H Jürgens, V Gerein, Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. Journal of Clinical Oncology. ,vol. 6, pp. 329- 337 ,(1988) , 10.1200/JCO.1988.6.2.329